Albany, NY -- (SBWIRE) -- 07/11/2017 -- The global ulnar nerve entrapment market is expected to grow substantially due to increasing investment in research and development by pharmaceutical companies, rising incidence rate of vascular diseases, and development of innovative products and advanced technology for the treatment of ulnar nerve entrapment. In addition ignore the pain associated with ulnar nerve, and high cost required for surgery fuel the growth of the market. However, long duration of treatment and limited budget of small and medium sized companies restrain the market.
The ulnar nerve is one of the major nerves in a human arm and travels from neck down to the hands. It controls movement and provides feeling for parts of hand. However, at times, ulnar nerve becomes compressed or physically trapped, resulting in pain, numbness, or weakness. This condition is known as ulnar nerve entrapment.
Depending on the location of entrapment, there are two types of ulnar entrapment: cubital tunnel syndrome and ulnar tunnel syndrome. Entrapment at the elbow in the cubital tunnel is termed as cubital tunnel syndrome. Ulnar tunnel entrapment occurs in anatomical space in the wrist. The common causes of ulnar nerve entrapment are forceful exercising and strain involving the elbow, bench pressing, and sleeping with the arm folded behind the neck. Weakness in hand, sensitivity to cold, and muscle wasting are the common symptoms of ulnar nerve entrapment. In the other hand treatment part, which includes there is no specific treatment for ulnar nerve entrapment but joint mobilizations, stretching exercises, neural flossing can be effective in ulnar nerve entrapment. If ulnar nerve pain is mild to moderate, then surgery is not required. Physicians prefer non-steroidal anti-inflammatory drug such as ibuprofen and others for treatment. However, when pain associated with ulnar nerve is quite severe, physicians advice surgery. Before surgery, physicians suggest physiological tests such as X-ray. These imaging tests provide detailed pictures of dense structures, like bone, and nerve conduction studies this test helps to identify where it is being compressed, and determine how well the nerve is working.
The global market of ulnar nerve entrapments are quite limited because it is still emerging at global level. The market has been segmented based on type of treatment, end-user, and region. In terms of type of treatment, the ulnar nerve entrapments market has been categorized into surgical and non-surgical. Non-surgical treatment includes medicines such as amitriptyline, NSAIDs, and vitamin B6 supplement, and devices such as supporter or splint. Based on end-user, the market has been segmented into hospitals, ambulatory surgical clinics, chronic & acute care, and sports. In terms of region, the ulnar nerve entrapment market has been segmented into North America, Asia Pacific, Europe, and Rest of the World. North America dominates the market as the U.S. is the major contributor in this region due to invention of advance technology, research & development in this area, rising prevalence of disorders, and other chronic diseases. Asia Pacific is also a fast growing market due to growing health care expanse and high patient base.
Key players operating in this market are Pfizer, Inc., Alkem Laboratories, Teva Pharmaceutical Industries Ltd., Apotex, Inc., Amneal Pharmaceuticals LLC, Aurobindo Pharma, and Mylan N.V., among others. In order to gain high market share in the industry, the key players are actively involved in variation in products, services, and periodic new product launches. Collaborations, partnerships, are agreements are some of the important strategies followed by the market players.
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Ulnar Nerve Entrapment Market during 2017- 2025